Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tubulin beta chain is a major structural protein that forms heterodimers with alpha-tubulin to create the building blocks of microtubules. Microtubules are dynamic cytoskeletal filaments essential for maintaining cell shape, enabling intracellular transport, segregating chromosomes during mitosis/meiosis, and facilitating cellular motility. The protein binds GTP at specific sites critical for its polymerization dynamics. Because of its central role in cell division and structure, the tubulin beta chain is a validated therapeutic target—especially in oncology—where drugs that disrupt its function are widely used as chemotherapeutics.[1][3][5][6]
Drugs targeting tubulin beta chain generally act by binding to tubulin and disrupting microtubule dynamics, either stabilizing or destabilizing microtubules. This interferes with mitosis and leads to cell cycle arrest and apoptosis in rapidly dividing cells such as cancer cells.[4]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin beta chain (TUBB).